EPIRUS Biopharma: Cash-strapped Epirus to sell CHO platform and biosimilar IP to Polpharma for $3.5m

As part of a cost-savings restructure, Epirus is selling the assets from its $14m acquisition of Bioceros last September to its biosimilars partner Polpharma.